Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon Extension in Mild Alzheimer's Disease
NCT02916056Phase 3Terminated
- Sponsor
- vTv Therapeutics
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of azeliragon in Alzheimer's disease (AD), sponsored by vTv Therapeutics. Primary endpoint: Number of Subjects With at Least One Treatment-Emergent Adverse Event at 18 months. Started Dec 2016; status: terminated.
02
Drugs
azeliragon
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02916056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916056.